BNP Paribas Financial Markets Reduces Holdings in LivaNova PLC (NASDAQ:LIVN)

BNP Paribas Financial Markets lessened its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 63.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 27,845 shares of the company's stock after selling 48,570 shares during the quarter. BNP Paribas Financial Markets owned 0.05% of LivaNova worth $1,463,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Driehaus Capital Management LLC boosted its position in LivaNova by 64.7% in the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company's stock valued at $29,824,000 after buying an additional 213,749 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in shares of LivaNova by 48.5% in the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company's stock valued at $24,340,000 after acquiring an additional 145,000 shares during the last quarter. Great Lakes Advisors LLC acquired a new stake in shares of LivaNova in the second quarter worth $16,614,000. Cornercap Investment Counsel Inc. purchased a new position in shares of LivaNova during the second quarter worth $1,103,000. Finally, Allspring Global Investments Holdings LLC lifted its position in LivaNova by 3.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company's stock valued at $41,889,000 after purchasing an additional 25,277 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Price Performance

NASDAQ LIVN traded up $0.27 on Monday, hitting $49.98. The company had a trading volume of 550,207 shares, compared to its average volume of 607,587. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market capitalization of $2.71 billion, a PE ratio of 119.00 and a beta of 0.98. LivaNova PLC has a 12-month low of $43.15 and a 12-month high of $64.47. The company's fifty day moving average price is $52.14 and its 200-day moving average price is $51.67.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. StockNews.com lowered LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Saturday, November 16th. The Goldman Sachs Group began coverage on LivaNova in a research report on Friday, October 4th. They set a "buy" rating and a $65.00 price target for the company. Mizuho dropped their price objective on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, October 31st. Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, Needham & Company LLC restated a "buy" rating and set a $75.00 price target on shares of LivaNova in a research report on Monday, November 25th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, LivaNova currently has an average rating of "Buy" and an average price target of $69.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.